|
Awakn Life Sciences CEO, Anthony Tennyson, Joins Dustin Robinson of Iter Investments for 'The Investor Hotseat' via Live Stream on May 26th
|
|
Awakn Life Sciences Corp.
|
May 24, 2022 07:30AM
|
|
Awakn Life Sciences Completes World's First Ketamine Treatment Study for a Range of Behavioral Addictions
|
|
Awakn Life Sciences Corp.
|
May 19, 2022 07:56AM
|
|
Awakn Life Sciences Drug Discovery Program Files Patent Application for a New Class of Entactogen-Like Molecules
|
|
Awakn Life Sciences Corp.
|
Feb 17, 2022 07:45AM
|
|
Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist
|
|
Awakn Life Sciences Corp.
|
Aug 15, 2022 09:00AM
|
|
Awakn Life Sciences Expands World's First Ketamine Study Beyond Gambling Disorder to Include Additional Behavioral Addictions
|
|
Awakn Life Sciences Corp.
|
Jan 05, 2022 07:30AM
|
|
Awakn Life Sciences Files Patent Application for a New Class of Entactogen-Like Molecules to Treat a Broad Range of Addictions
|
|
Awakn Life Sciences Corp.
|
Jan 26, 2022 07:30AM
|
|
Awakn Life Sciences Files Patent Applications in U.S. for AWKN001 and AWKN002, Two Next-Generation New Chemical Entities...
|
|
Awakn Life Sciences Corp.
|
Jun 28, 2021 07:30AM
|
|
Awakn Life Sciences Files Patent Cooperation Treaty (PCT) Application for the Treatment of Behavioral Addictions
|
|
Awakn Life Sciences Corp.
|
May 26, 2022 07:30AM
|
|
Awakn Life Sciences Identifies New Chemical Series via Its Drug Discovery Program
|
|
Awakn Life Sciences Corp.
|
Oct 28, 2021 07:30AM
|
|
Awakn Life Sciences Initiates Follow-On Behavioral Study to Focus on Gambling Disorder
|
|
Awakn Life Sciences Corp.
|
Jun 02, 2022 07:30AM
|
|
Awakn Life Sciences Initiates Research Program to Further Develop Ketamine-Assisted Therapies for Treating Addiction
|
|
Awakn Life Sciences Corp.
|
Jul 14, 2021 07:30AM
|
|
Awakn Life Sciences Initiates the First Ketamine Treatment Study for Gambling Addiction Led by Professor Celia Morgan
|
|
Awakn Life Sciences Corp.
|
Aug 24, 2021 07:30AM
|
|
Awakn Life Sciences Provides a Business and Corporate Update
|
|
Awakn Life Sciences Corp.
|
Jul 15, 2022 07:30AM
|
|
Awakn Life Sciences Provides Shareholder Update on Three Operational Ketamine-Assisted Therapy Clinics in the UK and Norway
|
|
Awakn Life Sciences Corp.
|
Apr 13, 2022 07:30AM
|
|
Awakn Life Sciences Receives Regulatory Approval for Flagship Clinic in London to Begin Delivering Treatments
|
|
Awakn Life Sciences Corp.
|
Mar 17, 2022 07:30AM
|
|
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development…
|
|
Awakn Life Sciences Corp.
|
Jul 05, 2022 07:42AM
|
|
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results
|
|
Awakn Life Sciences Corp.
|
Apr 28, 2022 04:28PM
|
|
Awakn Life Sciences Reports Fiscal Third Quarter 2021 Financial Results and Business Highlights
|
|
Awakn Life Sciences Corp.
|
Dec 15, 2021 07:30AM
|
|
Awakn Life Sciences Reports Results for Quarter Ended April 30, 2022
|
|
Awakn Life Sciences Corp.
|
Jun 14, 2022 04:00PM
|
|
Awakn Life Sciences Reports Second Quarter 2021 Financial Results and Business Highlights
|
|
Awakn Life Sciences Corp.
|
Sep 15, 2021 07:30AM
|
